The control of primary or secondary pleural effusions in patients with neoplasms constitutes a major clinical problem. The many drugs and physical agents that have been tried in the hope of stopping or at least slowing down the rate of accumulation include radioactive colloidal gold,' talc,2 doxorubicin,34 quinacrine,' tetracycline, ' nitrogen mustard,7 and bleomycin.8 The clinical results have been variable, with considerable side effects in some instances.
Recently attempts have been made to control the effusions with substances that besides producing pleural fibrosis might exert an immune-stimulating action at the site of pleural effusion. After completing a series of animal studies with intrapleural Corynebacterium parvum Israel' s group proposed intracavitary treatment with this agent for neoplastic effusions.9 '°Grant II conducted a comparative trial of intrapleural mustine hydrochloride versus Corynebacterium parvum and showed favourable results with the latter. Another report,'3 on six patients with neoplastic pleurisy or ascites, described good results in six cases, with quantitative reduction of effusion fluids and reduced malignant cell counts. In view of these reports we decided to attempt to verify the fibrosing and immunostimulant effects of intrapleural Corynebacterium parvum in our own patients. Ten patients were studied-four with secondary neoplastic pleurisy (three with lung carcinoma and one with ovarian adenocarcinoma), five with primary pleural mesothelioma, and one with an exclusively pleuropulmonary lymphoblastic lymphoma.
Methods
The patients were accepted for the Corynebacterium parvum trial when they had large pleural effusions necessitating frequent thoracocentesis for the relief of severe cough, dyspnoea, and pain. The neoplastic nature of these pleural effusions was ascertained by pleural biopsy in the five cases of primary neoplasms and confirmed by the detection of tumour cells in pleural fluids in the others. The diagnosis of mesothelioma was made histologically from needle biopsy specimens on the basis of the characteristic epithelial arrangements (tubulopapillary patterns) of the neoplastic cells, with scanty eosinophilic cytoplasm and an ovoid nucleus with well-developed nucleolus.
All 10 patients gave their informed consent in writing. The method consisted of draining as much pleural fluid as possible except the last 100 ml or so, and then injecting into the pleural cavity 7 mg of Corynebacterium parvum (Coparvax Wellcome: vial containing 7 mg (dry weight) of the killed Corynebacterium parvum organisms,. Wellcome strain CN6134, in a freeze-dried form); this was suspended in 20 ml of normal saline solution. There was no predetermined rate of further administration: each patient was treated as dictated by the amount of pleural fluid reforming after each thoracocentesis. In 22
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